Literature DB >> 23885640

Evaluation of new Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone peptides for melanoma imaging.

Adam M Flook1, Jianquan Yang, Yubin Miao.   

Abstract

The purpose of this study was to examine the melanoma targeting and imaging properties of two new (99m)Tc-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone (α-MSH) peptides. RTD-Lys-(Arg(11))CCMSH {c[Asp-Arg-Thr-Asp-DTyr]-Lys-Cys-Cys-Glu-His-DPhe-Arg-Trp-Cys-Arg-Pro-Val-NH2} and RVD-Lys-(Arg(11))CCMSH peptides were synthesized, and their melanocortin-1 (MC1) receptor binding affinities were determined in B16/F1 melanoma cells. The biodistribution and melanoma imaging properties of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH were determined in B16/F1 melanoma-bearing C57 mice. The IC50 values of RTD-Lys-(Arg(11))CCMSH and RVD-Lys-(Arg(11))CCMSH were 0.7 ± 0.07 and 1.0 ± 0.3 nM in B16/F1 melanoma cells. Both (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH displayed high melanoma uptake. (99m)Tc-RTD-Lys-(Arg(11))CCMSH exhibited the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h postinjection, whereas (99m)Tc-RVD-Lys-(Arg(11))CCMSH reached the highest tumor uptake of 19.63 ± 4.68% ID/g at 4 h postinjection. Both (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH showed low accumulation in normal organs (<1.7% ID/g) except for the kidneys at 2 h postinjection. The renal uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH was 135.14 ± 23.62 and 94.01 ± 18.31% ID/g at 2 h postinjection, respectively. The melanoma lesions were clearly visualized by single-photon emission computed tomography (SPECT)/CT using either (99m)Tc-RTD-Lys-(Arg(11))CCMSH or (99m)Tc-RVD-Lys-(Arg(11))CCMSH as an imaging probe at 2 h postinjection. Overall, the introduction of Thr or Val residue retained high melanoma uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH. However, high renal uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH need to be reduced to facilitate their future applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23885640      PMCID: PMC3866226          DOI: 10.1021/mp400248f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  25 in total

1.  A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis.

Authors:  Sylvie Froidevaux; Martine Calame-Christe; Heidi Tanner; Lazar Sumanovski; Alex N Eberle
Journal:  J Nucl Med       Date:  2002-12       Impact factor: 10.057

2.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Authors:  R Haubner; H J Wester; U Reuning; R Senekowitsch-Schmidtke; B Diefenbach; H Kessler; G Stöcklin; M Schwaiger
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

3.  Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.

Authors:  Jianquan Yang; Haixun Guo; Yubin Miao
Journal:  Nucl Med Biol       Date:  2010-07-24       Impact factor: 2.408

4.  Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide.

Authors:  Jianquan Yang; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2012-01-10       Impact factor: 2.823

5.  Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

6.  Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH.

Authors:  Paul McQuade; Yubin Miao; Jeongsoo Yoo; Thomas P Quinn; Michael J Welch; Jason S Lewis
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

7.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

8.  [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.

Authors:  Clemens Decristoforo; Bluma Faintuch-Linkowski; Ana Rey; Elisabeth von Guggenberg; Marco Rupprich; Ignacio Hernandez-Gonzales; Teodoro Rodrigo; Roland Haubner
Journal:  Nucl Med Biol       Date:  2006-11       Impact factor: 2.408

9.  (18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK).

Authors:  Christina Hultsch; Margret Schottelius; Jörg Auernheimer; Andrea Alke; Hans-Jürgen Wester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

10.  Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.

Authors:  Jianquan Yang; Haixun Guo; Fabio Gallazzi; Marianne Berwick; R Steven Padilla; Yubin Miao
Journal:  Bioconjug Chem       Date:  2009-06-24       Impact factor: 4.774

View more
  7 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

2.  Linker modification reduced the renal uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide.

Authors:  Jianquan Yang; Adam M Flook; Changjian Feng; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2013-11-23       Impact factor: 2.823

3.  Effects of amino acids on melanoma targeting and clearance properties of Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone peptides.

Authors:  Adam M Flook; Jianquan Yang; Yubin Miao
Journal:  J Med Chem       Date:  2013-11-04       Impact factor: 7.446

4.  Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.

Authors:  Sture Lindegren; Luciana N S Andrade; Tom Bäck; Camila Maria L Machado; Bruno Brasil Horta; Carlos Buchpiguel; Ana Maria Moro; Oswaldo Keith Okamoto; Lars Jacobsson; Elin Cederkrantz; Kohshin Washiyama; Emma Aneheim; Stig Palm; Holger Jensen; Maria Carolina B Tuma; Roger Chammas; Ragnar Hultborn; Per Albertsson
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

5.  Clickable, hydrophilic ligand for fac-[M(I)(CO)3](+) (M = Re/(99m)Tc) applied in an S-functionalized α-MSH peptide.

Authors:  Benjamin B Kasten; Xiaowei Ma; Hongguang Liu; Thomas R Hayes; Charles L Barnes; Shibo Qi; Kai Cheng; Shalina C Bottorff; Winston S Slocumb; Jing Wang; Zhen Cheng; Paul D Benny
Journal:  Bioconjug Chem       Date:  2014-02-25       Impact factor: 4.774

6.  Substitution of the Lys linker with the β-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated α-melanocyte stimulating hormone peptides.

Authors:  Adam M Flook; Jianquan Yang; Yubin Miao
Journal:  J Med Chem       Date:  2014-10-16       Impact factor: 7.446

Review 7.  Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor.

Authors:  Chengcheng Zhang; Kuo-Shyan Lin; François Bénard
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.